VLTS 934

Drug Profile

VLTS 934

Alternative Names: PINC polymer; Poloxamer

Latest Information Update: 14 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Valentis
  • Class Vascular disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Peripheral arterial occlusive disorders

Most Recent Events

  • 14 Jul 2006 Results from a phase IIb clinical trial in patients with intermittent claudication have been added to the adverse events and Vascular Disorders therapeutic trials sections
  • 11 Jul 2006 Discontinued - Phase-II for Peripheral arterial occlusive disorders in USA (unspecified route)
  • 16 Feb 2006 Valentis has completed enrolment in the phase IIb trial for Peripheral arterial disease in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top